Smac Antibody (56): sc-136302
- Smac Antibody (56) is a mouse monoclonal IgG2b, cited in 4 publications, provided at 50 µg/0.5 ml
- raised against amino acids 125-239 of Smac of human origin
- recommended for detection of Smac of mouse, rat, human and canine origin by WB and IP
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for Smac Antibody (56). This work is in progress.
QUICK LINKS
SEE ALSO...
Smac Antibody (56) is a mouse monoclonal IgG2b antibody that recognizes Smac in mouse, rat, human, and canine samples through applications such as western blotting (WB) and immunoprecipitation (IP). Smac, also known as second mitochondria-derived activator of caspase, plays a crucial role in regulating apoptosis by promoting caspase activation in the cytochrome c/Apaf-1/caspase-9 pathway. Smac is primarily located in mitochondria of healthy cells, where anti-Smac antibody (56) can detect its function in inhibiting the Inhibitors of Apoptosis Proteins (IAPs) that would otherwise prevent caspase activation. Upon apoptosis onset, Smac is released into the cytosol, where Smac (56) monoclonal antibody can monitor its binding to IAPs, effectively neutralizing their inhibitory effects and allowing for programmed cell death execution. Smac′s ability to modulate apoptosis is vital for maintaining cellular homeostasis and preventing uncontrolled cell proliferation, making Smac (56) antibody valuable for research in cancer and other diseases characterized by dysregulated apoptosis.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
Smac Antibody (56) References:
- Small-molecule SMAC mimetics as new cancer therapeutics. | Bai, L., et al. 2014. Pharmacol Ther. 144: 82-95. PMID: 24841289
- Smac Mimetics to Therapeutically Target IAP Proteins in Cancer. | Fulda, S. 2017. Int Rev Cell Mol Biol. 330: 157-169. PMID: 28215531
- SMAC mimetics as potential cancer therapeutics in myeloid malignancies. | Boddu, P., et al. 2019. Br J Haematol. 185: 219-231. PMID: 30836448
- Bivalent SMAC Mimetics for Treating Cancer by Antagonizing Inhibitor of Apoptosis Proteins. | Zhu, H., et al. 2019. ChemMedChem. 14: 1951-1962. PMID: 31692274
- SMAC Mimetics as Therapeutic Agents in HIV Infection. | Molyer, B., et al. 2021. Front Immunol. 12: 780400. PMID: 34899741
- Structural basis for regulation of apoptosis and autophagy by the BIRC6/SMAC complex. | Ehrmann, JF., et al. 2023. Science. 379: 1117-1123. PMID: 36758105
- Structural basis for SMAC-mediated antagonism of caspase inhibition by the giant ubiquitin ligase BIRC6. | Dietz, L., et al. 2023. Science. 379: 1112-1117. PMID: 36758106
- Combination of bazedoxifene with chemotherapy and SMAC-mimetics for the treatment of colorectal cancer. | Dmello, RS., et al. 2024. Cell Death Dis. 15: 255. PMID: 38600086
- SMAC mimetic drives microglia phenotype and glioblastoma immune microenvironment. | Snacel-Fazy, E., et al. 2024. Cell Death Dis. 15: 676. PMID: 39278921
- SPOP-mediated RIPK3 destabilization desensitizes LPS/sMAC/zVAD-induced necroptotic cell death. | Lee, GE., et al. 2024. Cell Mol Life Sci. 81: 451. PMID: 39540935
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Smac Antibody (56) | sc-136302 | 50 µg/0.5 ml | $322.00 |